Ajanta Pharma

AJANTPHARM (₹3,289.00) exhibits a near-term technical weakness against a longer-term bullish backdrop. On the daily chart, price action is below key short-term moving averages (20-day and 50-day EMA/SMA) and the Supertrend, which is bearish. Trend strength is weak, with an ADX of 14.49, indicating a lack of directional conviction despite recent volatility anomalies on October 30. The stock is trading in the lower half of its 20-day range (+21.2%) but remains well above its 200-day SMA, preserving the long-term uptrend.

Conversely, the monthly and weekly charts remain constructive. The monthly trend is strong (ADX 42.16) with price above all major averages and the Supertrend. The weekly structure also shows bullish momentum, with price above the 50-period averages and Supertrend. This divergence suggests that while short-term sellers are active, the broader intermediate and long-term trends have not yet been invalidated.

Key levels to monitor include immediate resistance at ₹3,308.37 (pivot) and ₹3,314.50 (high), with support nearby at ₹3,280.43 (low). A break below ₹3,280 could test lower support at ₹3,244.17. Conversely, a sustained move above ₹3,314.50 would be required to confirm a resumption of the daily uptrend. Volatility is elevated, with annualized volatility at +29.7% and current drawdown at -11.5%.

In the seven-day window leading up to November 6, 2026, the primary material development for Ajanta Pharma was a broker recommendation update. On November 2, brokerage firm Prabhudas Lilladher issued a 'Buy' rating for the company's shares, setting a price target of ₹4,250. This external analyst opinion provides a specific valuation benchmark and sentiment indicator for retail investors monitoring the stock. As with all third-party ratings, this view reflects the analyst's independent assessment and should not be interpreted as a guaranteed outcome or investment advice from Faxioms.

Ajanta Pharma Limited reported unaudited financial results for the quarter and half-year ended September 30, 2026, following a Board meeting on October 30, 2026. The company posted strong growth, with consolidated revenue from operations rising 33% to ₹1,794 crore in Q2 FY2027 (up from ₹1,354 crore) and profit after tax increasing 49% to ₹388 crore (up from ₹260 crore). For the first half of FY2027, consolidated revenue grew 29% to ₹3,420 crore, while profit after tax rose 40% to ₹722 crore. These figures were subject to limited review reports by B S R & Co. LLP, which indicated no material misstatements or disclosure omissions. An earnings call was held on October 30, 2026, with transcripts and recordings subsequently filed with the exchanges.

Ajanta Pharmaceuticals demonstrates a robust operating trajectory with accelerating top-line growth and improving profitability in the second quarter of FY2026-27. Revenue from operations rose sequentially to ₹1,794 crore, up from ₹1,626 crore in Q1, while net profit increased to ₹388 crore from ₹334 crore. This momentum is consistent with strong year-on-year trends, where TTM sales reached ₹6,217 crore (up from ₹5,453 crore in Mar 2026) and TTM net profit grew to ₹1,263 crore. Earnings quality remains high, evidenced by a Return on Equity of 27% for the last fiscal year and a Compounded Profit Growth of 30% over the trailing twelve months.

Financial health is supported by solid cash generation, though working capital dynamics require monitoring. Cash from Operating Activity was ₹529 crore in Mar 2026, down from ₹1,157 crore in Mar 2025, coinciding with an increase in the Cash Conversion Cycle to 246 days. The balance sheet shows total assets growing to ₹6,425 crore as of Sep 2026, with investments rising to ₹620 crore. Promoter holding decreased slightly to 63.47% in Sep 2026, while DIIs increased their stake to 21.94%. The company continues to invest in capacity, with Capital Work-in-Progress (CWIP) increasing to ₹327 crore as of Sep 2026.

Technical indicators for Ajanta Pharmaceuticals (NSE) present a mixed but cautionary near-term picture as of November 5, 2026. While the monthly trend remains bullish, the daily chart shows bearish momentum with the SuperTrend signaling downside pressure and negative slopes across key moving averages (EMA-20: -18.38; SMA-20: -50.03). The stock has experienced significant volatility, evidenced by an annualized volatility of +29.7% and an Average True Range (ATR) of 3.52%. Price action is currently constrained within a tight range between immediate support at ₹3,280.43 and resistance at ₹3,308.37, reflecting indecision. Short-term performance has been weak, with returns of -0.8% over one day, -5.7% over one month, and -7.9% over twenty days. Although the stock is up +26.0% year-over-year, it is currently trading in a current drawdown of -11.5% from its recent peak, with a historical maximum drawdown of -20.8%, indicating potential vulnerability to further corrections if support levels fail.